Scott T. Tagawa, M.D., MS, FACP, FASCO

Medical Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

Over the course of my career, I have been fortunate to work with and learn from leaders across the field of genitourinary oncology. I initially developed an interest in fighting cancer in medical school, and ever since have been working towards increasing the cure rate and decreasing suffering from these diseases. I feel fortunate to work with renowned colleagues in all relevant disciplines (including medical oncology, urology, radiation oncology, pathology, radiology, and translational scientists). As the Director of the Genitourinary (GU) Oncology Program, together with my colleagues, I am proud of our ongoing care and collaboration efforts working to make progress and make new therapies available to patients with cancers of the bladder, kidneys, prostate and testes. 

Biographical Info

Scott T. Tagawa, MD, MS, FACP, FASCO, is a Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his Medical Degree at the University of Southern California (USC) School of Medicine. After completing his Internship and Residency training at USC, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. Dr. Tagawa had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary (GU) Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medicine (WCM)  in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis (blood clotting) in people with cancer. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.

EDUCATION/TRAINING:

Georgetown University, Washington D.C. B.S.; 1993.

University of Southern California School of Medicine, Los Angeles, CA. M.D.; 1998.

Internship, Internal Medicine. University of Southern California Department of Medicine; June 1998 - June 1999.

Residency, Internal Medicine. University of Southern California Department of Medicine; July 1999 - June 2001.

Chief Resident, University of Southern California Department of Medicine, Los Angeles, CA.; July 2001 -June 2002.

Fellowship, Combined program in Hematology and Oncology. University of Southern California Department of Medicine, Divisions of Hematology and Oncology; July 2002 - June 2005.

Chief Fellow, Hematology; 2003-04.

Chief Fellow, Oncology; 2004-05.

Weill Cornell Graduate School of Medical Sciences, Masters of Science in Clinical Investigation; 2010.

Honors and Awards

Deans List Scholar, Georgetown University College of Arts and Sciences Dean's List Scholar, 1989, 1992 

Mid-Atlantic Academic All Conference Water Polo, Georgetown University, 1993

Dean's Scholar for the Junior/Senior Continuum, University of Southern California School of Medicine, 1998

Intern of the Year, USC Department of Medicine, 1999

Junior Resident of the Year, USC Department of Medicine, 2000

Senior Resident of the Year, USC Department of Medicine, 2001

Brautbar Teaching Award, USC Department of Medicine, 2001

Teacher of the Year, Division of Hematology, USC Department of Medicine, 2004

Chiron Immunotherapy Research Fellowship Award, 2004-05

Young Investigator Award, Prostate Cancer Foundation, 2008-2011

Super Doctors New York 2009 - annually through present

America's Top Doctors For Cancer 2009 - annually through present

NIH Loan Repayment Program, Clinical Research (Extramural) 2009-2011

Top Doctors: New York Metro Area (13th Ed)

WCMC Department of Medicine Investigator Award Runner Up 2010

Guide to America’s Top Oncologists

Clinical Research, Loan Repayment Program Competitive Renewal, National Institutes of Health (Extramural)

America’s Top Doctors for Cancer, Volume 7

Top Doctors, US News & World Report 2011 

Top Doctors: New York Metro Area, 17th Ed.

America’s Top Physicians (Castle-Connolly)

2015: Newsweek Top Doctors

America's Top Doctors: 14th Edition, 13th Edition, 12th Edition, 11th Edition 

America's Top Doctors: 2017, 2016

Top Doctors New York Metro Area: 2010 - annually through present

America's Top Doctors for Cancer: 10th Edition, 9th Edition, 8th Edition, 7th Edition, 5th Edition

Top Doctors: New York Metro Area: 18th Edition, 17th Edition, 16th Edition, 15th Edition, 14th Edition, 13th Edition

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Hematology)
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
Prostate Cancer
Bladder Cancer
Testicular Cancer
Kidney Cancer
Urologic Cancer
Urothelial Cancer
Penile Cancer
Thrombosis
Languages
English
Education 
  • M.S.
    Weill Graduate School of Medical Sciences of Cornell University
    2010
  • M.D.
    University of Southern California School of Medicine
    1998
Appointments 
  • Attending Physician
    NewYork-Presbyterian Hospital
  • Professor of Medicine
    Weill Cornell Medical College, Cornell University
  • Professor of Medicine in Urology
    Weill Cornell Medical College, Cornell University
Videos

Prostate Cancer Clinical Trials NY | Weill Cornell Medicine Genitourinary Oncology Program

Kidney Cancer Treatment NY | Weill Cornell Medicine Genitourinary Oncology Program

Scott Tagawa, M.D., M.S.

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
AbbVie Inc.
AIkido Pharma Inc.
Ambrx, Inc.
Amgen, Inc.
Astellas Pharmaceuticals US, Inc.
Atlab Pharma SAS
Bayer Healthcare Pharmaceuticals
Blue Earth Diagnostics, Inc.
Clarity Pharmaceutical
Clovis Oncology, Inc.
Convergent Therapeutics, Inc
Daiichi Sankyo, Inc.
Dendreon Corporation
Eisai, Inc.
Endocyte, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
Immunomedics, Inc.
Janssen Biotech Inc.
Karyopharm Therapeutics, Inc.
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
QED Therapeutics
Regeneron Pharmaceuticals, Inc.
Sanofi-Aventis
Seattle Genetics, Inc.
Telix Pharmaceuticals
Tolmar Pharmaceuticals, Inc.
Professional Services: 
Boston Scientific Corporation
Speaker/Lecturer: 
Amgen, Inc.
Dendreon Corporation
Ownership: 
AIkido Pharma Inc.
Convergent Therapeutics, Inc
Proprietary Interest: 
Gilead Sciences, Inc.
Other Interest: 
Merck
POINT Biopharma Inc.